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Abstract
The immune responses of humans and animals to insults 
(i.e. , infections, traumas, tumoral transformation and 
radiation) are based on an intricate network of cells and 
chemical messengers. Abnormally high inflammation 
immediately after insult or abnormally prolonged pro-
inflammatory stimuli bringing about chronic inflammation 
can lead to life-threatening or severely debilitating 
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diseases. Mesenchymal stem cell (MSC) transplant 
has proved to be an effective therapy in preclinical 
studies which evaluated a vast diversity of inflammatory 
conditions. MSCs lead to resolution of inflammation, 
preparation for regeneration and actual regeneration, and 
then ultimate return to normal baseline or homeostasis. 
However, in clinical trials of transplanted MSCs, the 
expectations of great medical benefit have not yet been 
fulfilled. As a practical alternative to MSC transplant, a 
synthetic drug with the capacity to boost endogenous 
MSC expansion and/or activation may also be effective. 
Regarding this, IMT504, the prototype of a major class 
of immunomodulatory oligonucleotides, induces in vivo 
expansion of MSCs, resulting in a marked improvement 
in preclinical models of neuropathic pain, osteoporosis, 
diabetes and sepsis. IMT504 is easily manufactured and 
has an excellent preclinical safety record. In the small 
number of patients studied thus far, IMT504 has been 
well-tolerated, even at very high dosage. Further clinical 
investigation is necessary to demonstrate the utility of 
IMT504 for resolution of inflammation and regeneration 
in a broad array of human diseases that would likely 
benefit from an immunoprotective/immunoregenerative 
therapy. 
Key words: Immunohomeostasis; Immunoprotection; 
Immunoregeneration; Inflammation; Mesenchymal stem 
cells; IMT504
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Core tip: Mesenchymal stem cell (MSC) transplant 
has been demonstrated to be an effective therapy 
in preclinical studies evaluating a vast diversity of 
inflammatory conditions. However, in clinical trials 
of transplanted MSCs, the expectations of great 
medical benefit have not yet been fulfilled. In this 
regard, IMT504, the prototype of a major class of 
immunomodulatory oligonucleotides, induces in vivo 
expansion of MSCs, resulting in a marked improvement 
in preclinical models of neuropathic pain, osteoporosis, 
diabetes and sepsis. IMT504 is easily manufactured and 
has an excellent preclinical safety record. Further clinical 
investigation is necessary to demonstrate the utility of 
IMT504 for resolution of inflammation and regeneration 
in a broad array of human diseases that are likely to 
benefit from an immunoprotective/immunoregenerative 
therapy.
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INTRODUCTION
Homeostasis (from the Greek: Homeo, meaning 
unchanging + stasis, meaning standing), is a concept 
that goes back to the old Greek philosophers who 
believed that harmony was a fundamental attribute of 
life and health. Empedocles (495-435 BC) hypothesized 
that all material comprised elements that were in active 
opposition or association, and that equilibrium was a 
necessary condition for subsistence of living entities. 
Thereafter, Hippocrates (460-375 BC) stated that 
healthiness is the tuneful equilibrium of the components 
of the body, and disease is the disorganized relationship 
of these components[1,2]. Lately, Claude Bernard 
(1813-1878) specified that “All of the vital mechanisms, 
however varied they may be, always have one goal: 
To maintain the uniformity of the conditions of life in 
the internal environment (milieu intérieur)”[3]. Finally, 
Cannon[4] (1871-1945) expanded Claude Bernard’s idea 
of constancy of the “milieu intérieur”, naming his theory 
“homeostasis”. 
According to Cannon, homeostasis was a number 
of coordinated changes in the internal environment, 
leading to the preservation of physiological parameters 
within defined limits. These parameters encompassed 
temperature, pH, blood pressure and many others. 
Furthermore, in Cannon’s view, homeostasis constancy 
requires communication among intelligent sensors able 
to identify unacceptable deviations. This concept of 
homeostasis is the most widely accepted nowadays, 
owing to its simplicity and physiologic rationale. 
The immune system contributes to homeostasis by 
protecting the organism from an invasion by foreign 
organisms, such as bacteria, fungus, virus and parasites, 
and by participating in the defense of the organism 
against tissue damage caused by trauma, cancer or 
metabolic disorders such as diabetes. The immune 
response is biphasic, with the first phase represented by 
the inflammatory reaction, which aims for the prompt 
elimination of the causes of body aggression. Inflam-
matory signals include cytokines, chemokines, biogenic 
amines and eicosanoids that induce changes in diverse 
processes ranging from alterations in local vascular 
responses to abnormal rise in body temperature. Thus, 
acute inflammatory signals are antagonists of the normal 
homeostatic signals[5]. The second phase of the immune 
response aims to restore the normal homeostatic 
parameters. This phase includes the clearing of debris 
from the “battlefield” created by invading pathogens and 
phagocytic cells, and then the reconstitution of tissue 
integrity and normal function. 
In order to proceed from the initial inflammatory 
phase to the reconstitution phase, a switch command 
needs to be turned on. Failure to make this switch results 
in chronic inflammation and consequently in diseases 
such as autoimmunity (i.e., diabetes, multiple sclerosis, 
lupus erythematous) and neurodegenerative diseases 
(i.e., Alzheimer’s disease). However, termination of acute 
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inflammation too early presents the risk of inadequate 
clearance of pathogenic microorganisms that can result 
in chronic infection. Therefore, gaining an understanding 
of the nature of the switching mechanism that connects 
the first and second phase of the immune response is 
important for the finding of new efficient treatments. 
Over the last few years, numerous studies have 
identified mesenchymal stem cells (MSCs) as the es-
sential elements in this switching mechanism[6], since 
transplant of autologous MSCs expanded in vitro or 
even allogenic MSCs results in significant salutary 
effects in animal models representing various inflam-
matory diseases[7-9]. On the other hand, in 2007, we 
discovered that treatment of rats with a novel class of 
immunomodulatory oligonucleotides (ODNs) (PyNTTTTGT 
ODNs) lacking CpG motifs, induces MSC expansion in 
bone marrow and blood, thus markedly increasing the 
therapeutic potential of the autologous MSC pool during 
pathologic conditions[10]. This discovery greatly advances 
the development of defined, easy-to-produce and fully-
controllable pharmaceuticals for treatment of inflam-
matory diseases. Such an exciting prospect as the one 
suggested by these studies prompted us to review the 
relevant information in the field of immunoprotection and 
immunoregeneration mediated by MSCs or ODNs of the 
PyNTTTTGT class.
MSCS AND IMMUNOMODULATION 
MSCs are non-embrionic multipotent cells characterized 
by the capability to differentiate into mesodermal 
cell, for instance osteoblasts, chondroblasts and adi-
pocytes[11,12]. MSCs are resident of bone marrow, 
adipose tissue, umbilical cord blood and may other 
tissues[13-15]. These cells do not express class I or class II 
major histocompatibility complexes, thereby permitting 
adoptive transfer of MSCs between hosts without 
inducing acute rejection.
In addition to their progenitor cell properties, 
phenotypical plastic MSCs are able to interrelate with 
constituents of the immune system, exhibiting anti-
inflammatory or pro-inflammatory properties depending 
on the milieu composition[16-18]. In general, MSCs adopt 
a pro-inflammatory phenotype (MSC1) during early 
microbial invasion or trauma, when the concentration 
of pro-inflammatory cytokines in the milieu is relatively 
low. Some important effects of MSC1 at the damaged 
body site are stabilization of a pro-inflammatory classic 
phenotype (M1) in resident macrophages and activation 
of antimicrobial properties of neutrophils[19-23]. 
As inflammation proceeds, pro-inflammatory cyto-
kines accumulate up to a critical level that switches 
differentiation of MSCs to an anti-inflammatory pheno-
type (MSC2). Abundant information has been published 
on the relationship between MSC2 and resolution 
of the inflammatory setting, and tissue protection 
and repair[24-34]. Some of the well-known anti-inflam-
matory effects mediated by MSC2 are skewing macro-
phages to the M2 immunosuppressive alternative 
phenotype[35-41], promoting T cells to T regulatory (Treg) 
cell differentiation[42-48], skewing monocyte-derived 
dendritic cells to a regulatory phenotype[49-54], inhibiting 
neutrophil influx and respiratory burst while maintaining 
or even increasing its phagocytic capacity[55-59], inhibiting 
mast cell degranulation[60-62], and inhibiting pro-
inflammatory activities of T cells[63-72], natural killer (NK) 
cells[73-79] and B cells[80-84]. Furthermore, throughout 
the numerous reports describing the regulatory role of 
MSCs attenuating (at some point) inflammation, several 
intercellular molecular signals have consistently emerged 
as relevant. For example, the cytokines interferon-
gamma (IFN-γ), interleukin (IL-6) and tumor necrosis 
factor-alpha (TNF-α), and also stimulation of the toll-
like receptor (TLR)3 and TLR4 have been proposed as 
main signals for switching MSC differentiation to its anti-
inflammatory and pro-resolving differentiation stage[85]. 
Once differentiated into the anti-inflammatory and 
pro-resolving phenotype MSC2, MSC communication 
with other cells is mediated by molecular signals such us 
prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase 
(IDO), TNF-inducible gene 6 protein (TSG-6), hepatic 
growth factor (HGF) and transforming growth factor-
beta 1 (TGF-β1). PGE2 is a bioactive lipid with early 
and late effects in the setting of inflammation. In the 
early stages, PGE2 stimulates vasodilatation, relocation 
and activation of macrophages, mast cells and neutro-
phils. Later on, PGE2 promotes differentiation of 
macrophages and monocytoid dendritic cells to an 
anti-inflammatory phenotype that suppresses NK cell 
and neutrophil inflammatory function and mast cell 
degranulation[86]. Variances in sensitivity, desensitization 
and activation of different signaling pathways among 
several PGE2 receptors accounts for this adaptable 
pattern of responses at different stages of the immune 
response[87]. TGF-β1 also presents biphasic activities, 
since its strong chemoattractive properties brings about 
a rapid incoming of T cells, granulocytes and macro-
phages that can contribute to inflammation but can 
also exert a potent anti-inflammatory response by con-
straining the synthesis of inflammatory cytokines and 
stimulating differentiation of naïve T cells to Treg cells[88]. 
IDO is an intracellular enzyme that catabolizes the 
production of kynurenine from tryptophan. Induction 
of IDO in the inflammatory setting results in arrest 
and functional anergy of CD8+ T cells, inhibition of 
differentiation of T helper (Th) cells to Th17 cells and 
activation of differentiation to Treg cells[89]. TSG-6 is 
an anti-inflammatory protein secreted by MSCs in 
response to inflammatory cytokines (i.e., IL-1 and 
TNF-α) that mediates suppression of dendritic cell 
maturation and function[90]. HGF is a morphogenic and 
growth factor secreted by MSCs that also has anti-
inflammatory activity by inhibition of the production 
of pro-inflammatory cytokines and by stimulation of 
macrophage  differentiation to the M2 phenotype[91]. 
Figure 1 displays a highly simplified representation 
of interactions between MSCs and other cells of the 
immune system during the anti-inflammatory phase 
4 March 26, 207|Volume 9|Issue 3|WJSC|www.wjgnet.com
of the immune defensive response. In addition, anti-
inflammatory MSCs directly or indirectly interact with 
resident cells at the site of inflammation, for example 
with oligodendrocytes in the central nervous system, 
with osteoblasts and osteoclasts in bones, with beta 
cells in pancreas, etc. Therefore, the ability to respond 
under such diverse circumstances requires a highly 
adaptable cell, such as MSCs, in order to orchestrate 
the appropriate response. 
PROSPECTIVE THERAPEUTIC USE OF 
MSC TRANSPLANT 
The central role of MSCs in maintaining tissue homeo-
stasis serves as the basis for their therapeutic appli-
cation in many diverse inflammatory disorders. A 
large number of reported studies representing a wide 
spectrum of diseases reinforce this expectation. For 
example, MSC transplant has proven to be beneficial 
in preclinical as well as clinical studies of heart 
disease[92-105], renal disease[106-142], lung disease[143-159], 
liver disease[160-175], neural system disease[176-204], bone 
damage[205-227], skin wound healing[228-244], autoimmune 
disease[245-265], infectious diseases and sepsis[266-287], 
allergies and asthma[288-306], graft vs host disease[307-325] 
and diabetes[326]. 
Despite the current enthusiasm about the broad 
potential clinical use of MSC transplant, some concerns 
have been growing about some potential issues as 
follows. 
Economic 
MSC-based treatments might be expensive if founded 
on autologous cells because of the need to take a 
biopsy for each patient, grow the cells in vitro, and 
perform the quality testing previously to the use of 
MSC for treatment. Furthermore, it is not sure that 
this process would produce enough cells as needed 
or if these cells would retain their phenotypical and 
functional characteristics after subculture. Convenient 
substitutes of autologous MSCs are allogeneic MSCs 
because they do not present immunologically significant 
surface molecules and in consequence do not provoke 
significant immune rejection to cell transplantation. 
Therefore, allogenic MSC can be multiplied, aliquoted 
and stored beforehand and used when needed for 
treatment. Still, several regulatory and safety issues 
concerning allogenic MSCs should be resolved as 
discussed below.
Reproducibility
Consistent results with allogeneic MSC therapies are 





























Figure 1  Mesenchymal stem cell immunosuppressive regulatory effects. MSCs are polarized to an immunosuppressive stage (MSC2) by a high relative 
concentration of pro-inflammatory cytokines such as IFN-γ and TNF-α. MSC2 induce macrophage polarization of monocytes and pro-inflammatory macrophages 
(M1) to the immunosuppressive stage M2 by secreting immunomodulatory mediators such as PGE2 and HGF. MSC2 also induce differentiation of Th and Th17 to 
T regulatory cells (Treg) by secretion of TGF-β1 and indoleamine 2,3-dioxygenase (IDO). Furthermore, MSC2 induce differentiation of mDCs to a regulatory anti-
inflammatory stage (mDCreg), inhibit mast cell degranulation, inhibit NK cell pro-inflammatory functions and suppresses neutrophil respiratory burst. MSC2-derived 
PGE2 contributes to all of these effects. Other cytokines that have been implicated in at least some of the MSC2 immune-suppressive effects are IL-6 and GM-CSF[8]. 
MSC: Mesenchymal stem cell; IFN-γ: Interferon-gamma; TNF-α: Tumor necrosis factor-alpha; PGE2: Prostaglandin E2; Th: T helper; HGF: Hepatic growth factor; 
TGF-β1: Transforming growth factor-beta 1; mDCs: Monocyte-derived dendritic cells; NK: Natural killer; IL-6: Interleukin-6; GM-CSF: Granulocyte macrophage-colony 
stimulating factor.
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certain prefixed limits. Nevertheless, each allogeneic 
MSC batch is originated from a different donor. This 
fact results in substantial variation among the cell 
batches excluding establishment of a master cell 
bank. Furthermore, the starting material (i.e., bone 
marrow aspirate) consists in several cell types, and 
current techniques to isolate MSCs can rarely result in 
a pure a cell preparation. This can be solved deriving 
the batch from a single cell; a fact that implays a long 
growth process that could result in undesirable random 
mutations.
Safety issues
MSC prepared from human tissues might hold retroele-
ments, retroviruses and other viruses, and many 
other pathogens. A handful of these pathogens can be 
detected using current assays. Microbial contaminants 
may also upset therapeutic potency of MSCs. In addi-
tion, the use of fetal calf serum during cell growing 
culture raises concern regarding transmition of prion-
associated diseases. 
Racionality of MSC treatment to stimulate tissue repair 
rest on the hypothesis that endogenous repair prompted 
by MSC expansion, activation and relocation from the 
patient’s own MSCs reservoirs is deficient in numerous 
pathological conditions. A reasonable alternative to cell 
infusion could be the use of a synthetic medicine aimed 
to stimulate expansion, activation and relocation of the 
patient endogenous stem cells, as long as the disease 
does not permanently altered these endogenous cells. 
Development of a medicine like this may solve most, of 
the above-stated difficulties connected with therapeutic 
applications of MSC transplant. 
In this regard, our research group has pursued 
study for several years on the properties of a major 
class of immunostimulatory ODNs with the capacity to 
stimulate in vitro and in vivo MSC expansion. Preclini-
cal studies indicate that these synthetic drugs are 
safe and competent in the treatment of several of 
the disorders that are responsive to MSC transplant. 
General properties of the prototype of these ODNs, 
named IMT504, will be briefly described in the following 
sections, with special emphasis on the ability of IMT504 
to promulgate endogenous recruitment of MSCs for 
regenerative medicine.  
IMMUNOMODULATORY 
OLIGONUCLEOTIDE IMT504 AND 
INFLAMMATORY DISEASE 
Oligonucleotides with regulatory activities on the 
immune system may be categorized into two major 
classes: (1) CpG ODNs, that include at least one 
CpG dinucleotide[327]; and (2) PyNTTTTGT ODNs, that 
include at least one PyNTTTTGT octanucleotide in 
(Py: Pyrimidine; N: Adenine, Cytosine, Thymidine or 
Guanine; T: Thymidine; G: Guanine)[328]. ODNs of both 
classes have as target cells B-cells and/or plasmacytoid 
dendritic cells (PDCs). 
The seal of CpG ODNs is their capability to stimulate 
secretion of IFN-α by PDCs interacting with the 
TLR9[329,330], a characteristic that is absent in members of 
the PyNTTTTGT class. On the other hand, hallmarks of 
the PyNTTTTGT class are induction of an efficient release 
into the milieu of granulocyte macrophage colony-
stimulating factor (GM-CSF) by NK and natural killer T 
(NKT) cells in collaboration with IL-2[331] and stimulation 
of MSCs[10], characteristics that are absent or poorly 
expressed in CpG ODNs. Interestingly, IFN-α inhibited 
the GM-CSF secretion stimulated by PyNTTTTGT ODNs, 
and reciprocally these ODNs inhibit the excretion of 
IFN-α stimulated by CpG ODNs via TLR9 in PDCs[331]. 
Therefore, this mutual interference between ODNs of 
the major classes of immunostimulatory ODNs sug-
gested that they stimulate different and incompatible 
immune response pathways[331]. 
Participation of MSCs in the pathway stimulated by 
PyNTTTTGT ODNs prompted us to hypothesize that 
these ODNs may modulate the inflammatory process, 
thereby stimulating the switch from the pro-inflam-
matory to the anti-inflammatory reconstructive stage of 
the immune response. To test this hypothesis, IMT504, 
the prototype of the PyNTTTTGT ODN class, was assayed 
as a therapeutic agent in animal models representing 
diverse medical conditions in which an MSC transplant 
had proven to be useful. The chosen animal models 
were of neuropathic pain, osteoporosis, diabetes and 
sepsis. A brief description of these preclinical studies is 
provided below.
Neuropathic pain
Neuropathic pain is a chronic, excruciating pain triggered 
by a injury or disease of the somatosensory system[332]. 
Typical symptoms of neuropathic pain include allodynia 
(an answer to painful stimulation that does not usually 
provoke discomfort), hyperalgesia (augmented pain 
induced by stimuli that usually provoke pain), and 
spontaneous pain[333]. While pain represents an adaptive 
response, acting as a protective mechanism that 
inform an organism of actual or potential tissue injury, 
neuropathic pain is thought as a maladaptive answer of 
the nervous system to harm[334]. MSC transplantation 
has proven to be effective for the treatment of neuro-
pathic pain in several preclinical studies[335-342]. In 
addition, parenteral treatment with IMT504 has been 
shown to ameliorate neuropathic pain in a rat model of 
peripheral nerve lesion even when administered several 
days after nerve injury[343] (Figure 2). 
Osteoporosis
Osteoporosis is a medical condition characterized 
by decreased bone strength that results in frequent 
fractures. Mechanistically, osteoporosis results from a 
pathological increase of the activity rate of osteoclasts 
vs osteoblasts[344]. Usually, osteoporosis has been 
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considered an exclusive endocrine disease; however, 
it is now well established that continuing inflammation 
plays an important role in the osteoporosis develop-
ment[344,345]. Pro-inflammatory cytokines (e.g., IL-6 
and TNF-α), stimulate osteoclastogenesis and inhibit 
osteoblastogenesis and anti-inflammatory cytokines 
(e.g., IL-4 and IL-10), inhibit osteoclastogenesis[344]. 
There are currently only a few preclinical studies that 
have been published on the effect of MSC transplant in 
osteoporotic animals, and results in these reports are 
encouraging[346,347]. Furthermore, in a study performed 
in an ovariectomized rat model of osteoporosis, we 
observed that parenteral treatment with IMT504 
results in a remarkable recovery of the bone structure, 
as indicated by morphometric characteristics such 
as trabecular volume, trabecular density, trabecular 
thickness and trabecular distance in the femur head 
(Figure 3).
Diabetes
Diabetes is a group of metabolic illnesses characterized 
by high blood glucose levels and altered metabolism 
of sugars, faty acids and proteins because of faults in 
insulin secretion, activity, or both[348]. Type 1 diabetes 
results from deficient insulin production by the pancreas 
and its cause is unknown. Symptoms are polyuria, 
polydipsia, continuous hunger, weight loss, visual 
alterations and fatigue. Type 1 diabetes patients are 
susceptible to a potentially lethal state of diabetic 
ketoacidosis.
Type 2 diabetes begins with the fail of cells to pro-
perly react to insulin. Symptoms are similar but usually 
less marked than those of type 1 diabetes. Type 2 
diabetes patients rarely results in ketoacidosis[349]. 
Although the cause of type 1 diabetes is unknown, 
contribution of the immune system in pancreas and 
other organs damage in type 2 diabetes is unquestion-
able[350]. The key pathogenic event appears to be 
damage of pancreatic β cells caused by the attack 
of autoreactive cytotoxic T cells resulting in chronic 
inflammation of the pancreatic islets[351]. 
In type 2 diabetes, a state of chronic inflammation 
encompassing innate and adaptive immune responses, 
is in genera accepted to be the primary alteration[352]. 
Since islet inflammation contributes to the loss of 
functional β cells in both type 1 and type 2 diabetes, 
anti-inflammatory therapies have emerged as a reason-
able option to current treatments. In particular, MSC 
transplant as a therapy in animal models of type 1 
and type 2 diabetes resulted effective[353-356]. In these 
studies, improvement of the glucose metabolism 
and regeneration of pancreatic islets were observed. 
Furthermore, parenteral treatment with IMT504 also 
markedly reversed pancreatic damage in a rat model 
of diabetes induced by one high-dose administration of 
streptozotocin[357]. A striking recovery of islet number 
and structure accompanied by lowering of glucose and 
rising of insulin concentration reaching normal levels 
was observed in diabetic animals during and after the 
treatment (Figure 4). Study of histological markers for 
pancreatic progenitor cell proliferation and differentiation 
and for active angiogenesis indicated that stimulation 
of the remaining resident pancreatic islet cells might be 
critical for success of the IMT504 treatment.
Sepsis
Sepsis is a syndrome of dysregulated systemic immune 
responses to an infection or to microbial pathogenic 
components[358]. Diabetes mellitus, lymphoproliferative 
disease, hepatic cirrhosis, extensive burning, severe 
trauma, use of intravenous or vesicular catheters, 
prosthesis and treatments with immunosuppressive 
medicines or intravenous drugs are frequent causes 
that contribute to acquisition of infections resulting in 
sepsis.
Stimuli prompting sepsis can be exogenous (i.e., 
infectious) or endogenous (i.e., severe trauma) resulting 
in gut hypoperfusion, impaired epithelial barrier function 
and translocation of luminal bacteria and/or their toxins 
into the systemic circulation. Pathogen-associated 
molecular patterns and damage-associated molecular 
patterns are recognized by pattern recognition recep-
tors. These alarm signals activate systems in charge 
of keeping homeostasis. However, during sepsis, this 
system becomes dysregulated, leading to multiple 
organ damage.
During a first phase of sepsis, oxygen and nitrogen 
reactive forms accumulate. Some symptoms corre-
sponding to this period include tachycardia, fever and 
neutrophilia. This is quickly followed by a marked 
elevation of proinflammatory cytokines and chemokines 
in plasma as well as the migration of polymorphonuclear 
leukocytes, monocytes and lymphocytes to affected 
tissues. Owing to this dramatic presentation, the pre-
valent and long-time definition for sepsis has been 
that of an uncontrolled inflammatory response. How-
ever, a number of recent observations have led to a 
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Figure 2  Effect of IMT504 or mesenchymal stem cell treatment on the 
development of mechanical allodynia in rats. Sciatic nerve crush induced 
a significant decrease in paw withdrawal threshold to the von Frey filaments. 
It is noticeable that the administration of either IMT504 or MSCs prevents the 
development of allodynia. Experimental details are described in Coronel et 
al[343]. MSC: Mesenchymal stem cell.
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in sepsis there exist successive pro-inflammatory and 
anti-inflammatory (immunosuppressive) periods. Even 
though some patients die during the first pro-inflam-
matory period, due to septic shock, most patients 
survive it presently[360]. The great majority of deaths 
occur during the immunosuppressive period, which 
in general starts between the second and third day of 
sepsis and could persist for several weeks. In spite of 
antibiotic treatment and strong medical supportive care, 
many patients cannot eradicate the infection and may 
acquire secondary intra-hospital infections[361]. 
MSC transplant has been protective in preclinical 
animal models of polymicrobial sepsis[282,270] as well as 
in infections caused by bacterial strains of Escherichia 
coli, Pseudomonas aeruginosa and Staphylococcus 
aureus[266,284,362]. The protective role of MSCs in sepsis 
has been mainly attributed to their broad paracrine 
modulatory properties[269]. On the other hand, remark-
able protection against Pseudomonas infection was 
obtained in neutropenic rats in response to IMT504 
treatment[363]. Protection was 90%-100% using either 
early or late intervention after infection on par with 
antibiotic treatment (Figure 5). IMT504 treatment 
resulted in a marked decrement in serum IL-6 and in 
bacterial load in organs such as lungs, liver and spleen.
PRACTICAL CONSIDERATIONS 
REGARDING THE PROSPECTIVE 
CLINICAL USE OF IMT504 FOR 
TREATMENT OF INFLAMMATORY 
DISEASES
IMT504 is a drug with a well-defined formula that is 
relatively easy to synthesize using a rapid automatic 
process under GMP conditions and at reasonable cost if 
large quantities are required. In addition, formulations 
of IMT504 are not problematic because IMT504 is 
highly soluble. Additionally, once injected using different 
routes, IMT504 has a rapid and broad distribution[364]. 
Moreover, because IMT504 has good thermal stability, 
Trabecular bone volume (%) Trabecular number (#/mm)
Trabecular thickness (mm) Trabecular separation (mm)
Control (non-OVX)    OVX + saline       OVX + IMT504         Control (non-OVX)      OVX + saline       OVX + IMT504













Figure 3  Effect of the IMT504 treatment on bone structure in ovariectomized (osteoporotic) rats. Female Sprague-Dawley 16-week-old rats underwent 
ovariectomy (OVX). When animals were 1-year-old, half of them (treated group) received a subcutaneous dose of IMT504 (20 mg/kg per dose in saline) injected 
daily for 5 successive days. The other half-received saline under the same scheme (non-treated group). The treatment was repeated 30 d later. A group of non-
OVX rats served as control. Body weight and general health was measured weekly. One month after the last treatment, animals were euthanized and femurs 
dissected, decalcified and embedded in paraffin. Slides of 0.5-µm sections of the distal femur were generated using a Leica RM2145 microtome, stained with 
hematoxylin and eosin, and examined by light microscopy. Digital images were recorded with a Nikon Coolpix 4500 camera at 16.5-fold magnification under a Leica 
MZ16A stereomicroscope. Three fields in each slide were evaluated, totaling a combined area of 3 mm2. Trabecular bone was identified, and its perimeter and 


















0                           10                         20                          30
IMT504 injection
Time (d)
STZ            STZ + IMT504           Saline
Figure 4  IMT504 treatment induced a marked recovery of the diabetic 
condition in streptozotocin-treated rats. Arrows indicate IMT504 treatment, 
which consisted of daily subcutaneous injections containing 4 mg of IMT504 
over 10 successive days. Experimental details are described in Bianchi et al[357]. 
STZ: Streptozotocin.
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extreme conditions of transport and storage are not 
necessary. Finally, IMT504 preclinical toxicity studies 
performed in several animal species, including non-
human primates, indicate that IMT504 is a very safe 
drug with few secondary effects that are well-tolerated 
and within the therapeutic range of this agent[364,365]. 
WHAT DO WE KNOW ABOUT THE 
MECHANISM OF ACTION OF IMT504 ON 
THE IMMUNE SYSTEM? 
Known direct cell targets of IMT504 are B cells, PDCs, 
CD56+ cells (NK and NKT cells) and MSCs[10,328,331].
B cells
B cells contribute to the immune response by producing 
antibodies and stimulating T cell activation[366]. Besides, 
B cells can act as professional antigen-presenting cells 
(APCs) and B cell antigen presentation is essential for 
specific CD4+ T cell expansion, memory development 
and cytokine secretion[367,368]. CD80, CD86, and CD40 
surface components of B cells are essential for optimal 
T cell activation[369]. Furthermore, in inflammation and 
autoimmunity, B cells exert an immunomodulatory role 
in part by IL-10 production and secretion[370]. In vitro 
stimulation of human immature B cells with IMT504 
results in cell proliferation, MHC I, MHC II, CD40, CD80 
and CD86 cell surface expression, immunoglobulin 
secretion, and IL-6 and IL-10 secretion[328]. Furthermore, 
upon stimulation with IMT504, B cell transcripts for most 
of the components of the proteasome are significantly 
augmented (our unpublished results). Most of these 
effects indicate that IMT504 incubation empowers B 
cells for competent presentation of antigens to CD4+ 
T cells. In line with this, addition of IMT504 to different 
vaccines greatly increases their activity[371-373]. However, 
the strong secretion of IL-6 and IL-10 induced by 
IMT504 suggests that IMT504-activated B cells may 
also participate in regulation of the immune response.
PDCs
PDCs are dendritic cells specialized in producing type 
I IFNs when stimulated by nucleic acids through TLRs 
7 and 9[374]. Additionally, PDC stimulation by nucleic 
acids results in surface expression of MHC I, MHC II, 
CD40, CD80 and CD86[375]. Consequently, PDCs can 
present antigens to CD4+ T cells, leading to activation or 
tolerance depending on the context[375,376]. PDCs are also 
involved, by unrestrained IFN type I secretion, in several 
inflammatory autoimmune diseases such as multiple 
sclerosis, psoriasis, systemic lupus erythematosus and 
inflammatory bowel disease[377]. In vitro, stimulation 
of human immature PDCs with IMT504 also results in 
surface expression of MHC I, MHC II, CD40, CD80 and 
CD86[328]. However, in contrast with CpG ODNs, IMT504 
does not induce IFN type I secretion. Furthermore, 
incubation with IMT504 inhibits PDC IFN type I secretion 
induced by CpG ODNs[331]. Interestingly, this inhibition 
of the IFN type I secretion allows activation of CD56+ 
(NK and NKT) cells by IMT504 in collaboration with IL-2, 
resulting in strong secretion of IFN-γ, TNF-α and GM-
CSF[331]. 
CD56+ (NK and NKT) cells 
NK cells are innate lymphoid cells involved directly 
in the immune protection through cytotoxicity and 
cytokine secretion, and indirectly by modulating APCs 
and T cells[378]. The cytotoxic activity of NK cells depends 
on the release of lytic molecules toward target cells. NK 
cells can stimulate inflammation by excreting cytokines 
(e.g., IFN-γ and TNF-α); however, they can also limit 
inflammation and autoimmunity[379,380]. 
On the other hand, NKT cells specialized in 
recognition of lipid antigens presented by an MHC I-like 
antigen (CD1d). NKT cells also are able to modulate 
the immune responses involved in inflammation and 
autoimmunity[381]. Incubation of human PBMCs with 
IMT504 results in strong secretion of IFN-γ, TNF-α 
and GM-CSF, providing that IL-2 is present in the 
milieu[331]. IL-2 induces synthesis of the cytokines, and 
the presence of an ODN is necessary for their efficient 
secretion. CD56+ (NK and NKT) cells are responsible for 
the cytokine secretion and IFN-α inhibits the process. 
Induced cytokine secretion depends on two different 
IMT504 activities: (1) inhibition of the TLR9 dependent 
IFN-α secretion from PDCs; and (2) activation of a 
pathway of cytokine secretion presumably similar to 
the one described by Rao et al[382]. This last effect does 
not depend on the nucleotide sequence since ODNs 
with very diverse compositions were able to stimulate 
cytokine secretion when acting on purified CD56+ 
cells[331]. 
Figure 6 shows a schematic representation of the 

















IMT504 treated              Control            Antibiotic
Figure 5  IMT504 protects neutropenic animals from fatal Pseudomonas 
aeruginosa bacteremia and sepsis. Kaplan-Meier survival plot representing 
IMT504 monotherapy vs antibiotic (cefepime) monotherapy vs control. IMT504 
daily doses were started at day 5 after bacterial infection. Arrows indicate 
IMT504 treatment, which consisted of subcutaneous injections containing 50 g 
of IMT504 over 5 successive days. Experimental details described in Chahin et 
al[363].
9 March 26, 207|Volume 9|Issue 3|WJSC|www.wjgnet.com
activation as well as resolution of excessive inflammation 
by MSC expansion and secretion of cytokines necessary 
for MSC differentiation to the MSC2 anti-inflammatory 
stage. This scenario is congruent with the results of the 
above-described IMT504 preclinical assays involving 
animal models of neuropathic pain, osteoporosis, dia-
betes and sepsis. 
CONCLUSION
The immune homeostatic response of animals to 
aggression (infections, traumas, tumoral transformation, 
radiation, etc.,) is based on an intricate network 
of cells and chemical messengers. Abnormally 
high inflammation immediately after aggression or 
abnormally prolonged pro-inflammatory stimulus 
bringing about chronic inflammation are associated with 
life-threatening and severe debilitating diseases[383]. In 
both cases, albeit with different urgency, therapeutic 
intervention to restore homeostasis of the immune 
system is necessary. Current interventions mainly rest 
on positive or negative action on a particular element 
of the immune network abnormally represented 
in a specific immune disorder. However, given the 
complexity of the immune network and the general 
pleiotropism of its components, the effect of such 
interventions is often poor or even contradictory with 
the “a priori” rationality[384,385]. An exception is the 
transplantation of MSCs, which has demonstrated to 
be effective in preclinical studies representing a vast 
array of inflammatory conditions. Unfortunately, results 
from clinical trials involving transplantation of MSCs, 
in general, have not fulfilled expectations. Cell dosing 
and/or cell preconditioning seem to be critical issues that 
should be further studied in order to improve human 
treatments. As an alternative to MSC transplantation, 
a synthetic drug with the capacity to boost human 
MSC expansion and/or activation in vivo may also be 
effective, while avoiding many of these problems. 
Regarding this, we have reported that IMT504, the 
prototype of a major class of immunomodulatory ODNs, 
induces in vivo expansion and likely activation of MSCs. 
This effective endogenous recruitment of MSCs by 
IMT504 for regenerative medicine results in a marked 
improvement of animals’ chronic suffering as well as 
acute inflammatory disorders such as neuropathic pain, 
osteoporosis, diabetes and sepsis. IMT504 can be easily 
synthesized, purified and mass produced, and has an 
excellent preclinical safety record. In the small number 
of patients studied thus far, IMT504 has been well-
tolerated, even at very high dosage. Further clinical 
investigation is necessary to demonstrate the utility of 
IMT504 for resolution of inflammation and regeneration 
in a broad array of human diseases that are likely to 
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Figure 6  IMT504 effects on the immune system. Primary targets of IMT504 are B lymphocytes (B), PDCs, NK and NKT cells. IMT504 acting on B and PDCs 
induces a phenotype of antigen presenting cells, which in the presence of an appropriate antigenic stimulus initiates a strong adaptive immune response[371-373]. On the 
other hand, IMT504 acting on NK and NKT cells, in collaboration with IL-2, induces the strong secretion of IFN-γ and TNF-α that can induce MSC immunosuppressive 
properties and of GM-CSF that can activate MDSCs. This immunosuppressive pathway is inhibited by the presence of IFN-α. Reciprocally, IMT504 inhibits IFN-α 
secretion by PDCs. Therefore, activation of this immunosuppressive pathway depends on the balance between IMT504 activity and activity of IFN-α inducers that are 
present[331]. PDCs: Plasmacytoid dendritic cells; NK: Natural killer; NKT: Natural killer T; IL-2: Interleukin-2; IFN-γ: Interferon-gamma; TNF-α: Tumor necrosis factor-
alpha; GM-CSF: Granulocyte macrophage colony-stimulating factor; MDSCs: Myeloid-derived suppressor cells.
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